Written Question · S1W-11606 · Session 1
Further to the answer to question S1W-9625 by Susan Deacon on 15 November 2000, what criteria are used by specialists to determine whether …
The question
To ask the Scottish Executive, further to the answer to question S1W-9625 by Susan Deacon on 15 November 2000, what criteria are used by specialists to determine whether or not, in their clinical judgement, a patient should receive Transtu'mab (Herceptin) for the treatment of metastatic cancer and whether such criteria are standardised and practised across all health boards.
The answer
It is not possible to define precisely the criteria used by specialists in deciding whether an individual patient should receive Transtuzmab (Herceptin). The ultimate judgement regarding the use of a particular treatment will be made by the specialist in discussion with the patient, or the patient's carer, taking into account evidence from various sources such as the product literature provided by the manufacturer, information from clinical studies, publications such as professionals journals and advice from bodies like Area Drugs and Therapeutics Committees and the Health Technology Board for Scotland.
In the Official Report
No contribution in the Official Report cites S1W-11606 by reference.